Diagnostic value of using a combination of nucleic acid and specific antibody tests for SARS-CoV-2 in coronavirus disease 2019

Epidemiol Infect. 2021 Feb 17:149:e62. doi: 10.1017/S0950268821000406.

Abstract

Coronavirus disease 2019 (COVID-19) is a newly emerged disease with various clinical manifestations and imaging features. The diagnosis of COVID-19 depends on a positive nucleic acid amplification test by real-time reverse transcription-polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the clinical manifestations and imaging features of COVID-19 are non-specific, and nucleic acid test for SARS-CoV-2 can have false-negative results. It is presently believed that detection of specific antibodies to SARS-CoV-2 is an effective screening and diagnostic indicator for SARS-CoV-2 infection. Thus, a combination of nucleic acid and specific antibody tests for SARS-CoV-2 will be more effective to diagnose COVID-19, especially to exclude suspected cases.

Keywords: Antibody; COVID-19; SARS-CoV-2; nucleic acid.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Bacterial Agents / therapeutic use
  • Antibodies, Viral / blood
  • Antibodies, Viral / immunology
  • COVID-19 / diagnosis*
  • COVID-19 / pathology
  • COVID-19 Drug Treatment
  • COVID-19 Testing*
  • Diagnosis, Differential
  • Female
  • Humans
  • Lung / diagnostic imaging
  • Lung / pathology
  • Pneumonia, Bacterial / diagnosis*
  • Pneumonia, Bacterial / drug therapy
  • Pneumonia, Bacterial / pathology
  • RNA, Viral / analysis
  • RNA, Viral / genetics
  • SARS-CoV-2 / genetics
  • SARS-CoV-2 / immunology
  • SARS-CoV-2 / isolation & purification*
  • Treatment Outcome
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Antibodies, Viral
  • RNA, Viral